Rocket Pharmaceuticals shares plummeted 60% Tuesday after the firm said it halted a study of a gene-therapy drug for Danon disease because a patient had a "Serious Adverse Event (SAE)" and later died.

A patient has died in a clinical trial evaluating a Rocket Pharmaceuticals gene therapy shortly after complications emerged that led the FDA to pause the study. An inquiry into the fatality is ...

The FDA has slapped a clinical hold on Rocket Pharmaceuticals’ pivotal gene therapy trial in response to a death. Rocket, which was aiming to report data in mid-2026, dropped its targeted trial ...

Rocket Pharmaceuticals acknowledged the death of a patient in a pivotal trial assessing its Danon disease gene therapy candidate RP-A501, a study that the FDA has placed on clinical hold. The ...

Shares in Rocket Pharmaceuticals have been living up to their name, shooting up following encouraging early-stage clinical trial results from a gene therapy for a serious inherited rare heart disease.

Rocket Pharmaceuticals Inc. overhyped its treatment for a rare genetic disorder before revealing a patient from its clinical trial had died and that a federal agency had placed a hold on the study, ...

Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene ...

The U.S. FDA has paused Rocket Pharmaceuticals' mid-stage gene therapy trial after a patient died from serious complications, the drug developer said on Tuesday, sending its shares tumbling as much as ...

Jefferies lowered Rocket's price target to $2.50 from $29, citing safety concerns. Ready to turn the market’s comeback into steady cash flow? Grab the top 3 stocks to buy right here. A patient ...